AVBP Stock Summary and Trading Ideas (Arrivent Biopharma | NASDAQ:AVBP)

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

Arrivent Biopharma trades on the NASDAQ stock market under the symbol AVBP.

As of January 13, 2026, AVBP stock price declined to $20.36 with 15,201 million shares trading.

AVBP has a beta of 1.10, meaning it tends to be more sensitive to market movements. AVBP has a correlation of 0.13 to the broad based SPY ETF.

AVBP has a market cap of $840.49 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that AVBP belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.

AVBP has underperformed the market in the last year with a price return of -18.2% while the SPY ETF gained +21.2%. AVBP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -2.4% and -3.7%, respectively, while the SPY returned +6.9% and +1.2%, respectively.

AVBP support price is $19.73 and resistance is $21.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVBP shares will trade within this expected range on the day.